Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China
|ClinicalTrials.gov Identifier: NCT00757744|
Recruitment Status : Completed
First Posted : September 23, 2008
Last Update Posted : May 18, 2011
|Condition or disease||Intervention/treatment||Phase|
|Opiate Dependence HIV Infections||Behavioral: Behavioral Drug and HIV Risk Reduction Counseling (BDRC) Behavioral: Drug counseling||Phase 3|
This project is a supplement to a parent grant, Drug Counseling and Abstinence-Contingent Take-Home Buprenorphine in Malaysia. The specific aims of the parent grant include evaluating whether the relatively minimal counseling and other services provided with standard buprenorphine maintenance treatment (Standard BUP) is sufficient or whether one or a combination of two enhanced behavioral treatments--behavioral drug and HIV risk reduction counseling (BDRC) or abstinence-contingent take-home buprenorphine (ACB)—improve its efficacy (Specific Aim 1) and are cost-effective, with regard to the direct economic costs of providing the treatments (Specific Aim 2) and also to provide training and mentoring in drug abuse treatment and HIV prevention research to clinical researchers and clinical training for health professionals in Malaysia (Specific Aim 4). BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in developing countries.
The specific aims of the proposed study are consistent with the specific aims of the parent grant and include evaluating in a pilot, randomized clinical trial in a methadone treatment program in Wuhan, China, the feasibility and potential efficacy for reducing illicit drug use and HIV risk behaviors of BDRC when combined with standard methadone treatment services (Standard Methadone) compared to Standard Methadone only (Specific Aim 1 of the proposed study). Additional Specific Aims of the proposed study include developing estimates of the treatment costs and cost-effectiveness of Standard Methadone and BDRC (Specific Aim 2 of the proposes study), and providing training and mentoring in drug abuse treatment and HIV prevention research to clinical researchers an clinical training for health professionals in China (Specific Aim 3 of the proposed study).
Specific aims of the China project:
- Conduct a preliminary evaluation of the feasibility, acceptability, and preliminary efficacy for increasing treatment retention and reducing drug use and HIV risk behaviors of Behavioral Drug and HIV Risk Reduction Counseling (BDRC) when combined with Standard Methadone, in comparison to Standard Methadone, among opiate dependent treatment seeking volunteers admitted to the Wuhan Methadone Clinic.
- Develop estimates of the costs and cost-effectiveness of Standard Methadone and BDRC.
- Train and provide ongoing clinical supervision to a core group of 10 drug counseling staff and provide additional mentoring in drug abuse and HIV risk reduction research to investigators in China.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||45 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Official Title:||Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China|
|Study Start Date :||September 2007|
|Primary Completion Date :||January 2010|
|Study Completion Date :||September 2010|
Methadone maintenance treatment with Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
Behavioral: Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
once weekly individual counseling
Active Comparator: B
Methadone maintenance treatment with standard drug counseling
Behavioral: Drug counseling
individual drug counseling
- Reductions of illicit opiate use [ Time Frame: 6 months ]
- Reductions in HIV risk behaviors [ Time Frame: 6 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00757744
|United States, Connecticut|
|Yale University School of Medicine - CMHC|
|New Haven, Connecticut, United States, 06520|
|Wuhan Center for Disease Control and Prevention|
|Wuhan, Hubei, China|
|Principal Investigator:||Richard S Schottenfeld, MD||Yale University|